361 related articles for article (PubMed ID: 29453385)
1. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK
Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385
[TBL] [Abstract][Full Text] [Related]
2. Predictive Value of
Song BI; Kim HW; Won KS
Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
5. Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography, sonography, and sonographically guided fine-needle aspiration biopsy in the diagnosis of axillary lymph nodes in patients with breast cancer: comparison of diagnostic performance.
Sohn YM; Hong IK; Han K
J Ultrasound Med; 2014 Jun; 33(6):1013-21. PubMed ID: 24866608
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of SUV
Diao W; Tian F; Jia Z
Eur J Radiol; 2018 Aug; 105():1-7. PubMed ID: 30017264
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and volume-based parameters of (18F)FDG PET/CT for primary mass and axillary lymph node metastasis in patients with invasive ductal carcinoma: a retrospective analysis in relation to molecular subtype, axillary lymph node metastasis and immunohistochemistry and inflammatory markers.
Can C; Komek H
Nucl Med Commun; 2019 Oct; 40(10):1051-1059. PubMed ID: 31365497
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
[TBL] [Abstract][Full Text] [Related]
11. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
[TBL] [Abstract][Full Text] [Related]
13. Lymph node to primary tumor SUV ratio by 18F-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer.
Park J; Byun BH; Noh WC; Lee SS; Kim HA; Kim EK; Choi CW; Lim SM
Clin Nucl Med; 2014 Apr; 39(4):e249-53. PubMed ID: 24152622
[TBL] [Abstract][Full Text] [Related]
14. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
15. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
16. A machine learning-based radiomics model for the prediction of axillary lymph-node metastasis in breast cancer.
Song BI
Breast Cancer; 2021 May; 28(3):664-671. PubMed ID: 33454875
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis.
He X; Sun L; Huo Y; Shao M; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388
[TBL] [Abstract][Full Text] [Related]
18. Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI.
Yoo J; Kim BS; Chung J; Yoon HJ
Medicine (Baltimore); 2017 Aug; 96(31):e7657. PubMed ID: 28767583
[TBL] [Abstract][Full Text] [Related]
19. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
Choi WH; Yoo IR; O JH; Kim SH; Chung SK
Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
[TBL] [Abstract][Full Text] [Related]
20. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
